Intra-pleural Alteplase with Pulmozyme

PreclinicalSmall molecule

Intra-pleural Alteplase with Pulmozyme is one of 3 small molecule programs targeting Pleural Infection. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pleural InfectionCompleted

Pleural InfectionPreclinical

Completed

Competition

Competitive Landscape

2 competitors in Pleural Infection

#DrugCompanyPhaseTrials

Amoxicillin-Clavulanic Acid

Teva

Preclinical

1 2

Antibiotic Withdrawal

CCentre Hospitalier Universitaire, Amiens

Preclinical

1 3

Intra-pleural Alteplase with Pulmozyme

NNational University of Malaysia

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pleural Infection1 trial

Short Duration High Intensity Intrapleural Alteplase With Pulmozyme in Pleural Infection Management

Completed·NNational University of Malaysia·N/A·NCT04915586·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intra-pleural Alteplase with Pulmozyme. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intra-pleural Alteplase with Pulmozyme compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intra-pleural Alteplase with Pulmozyme. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National University of Malaysia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNational University of Malaysia

Intra-pleural Alteplase with Pulmozyme

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pleural Infection1 trial

References

Drug Info

Quick Facts

Related News